IDEXX Laboratories, Inc. $IDXX Shares Sold by Aberdeen Group plc

Aberdeen Group plc trimmed its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 89,983 shares of the company’s stock after selling 1,280 shares during the period. Aberdeen Group plc owned approximately 0.11% of IDEXX Laboratories worth $60,876,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Linden Thomas Advisory Services LLC grew its stake in shares of IDEXX Laboratories by 0.4% in the fourth quarter. Linden Thomas Advisory Services LLC now owns 7,856 shares of the company’s stock valued at $5,315,000 after buying an additional 31 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its stake in IDEXX Laboratories by 73.0% during the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 614 shares of the company’s stock worth $415,000 after purchasing an additional 259 shares during the period. Essential Planning LLC. purchased a new stake in IDEXX Laboratories during the fourth quarter worth about $378,000. Lodestone Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories during the fourth quarter worth about $43,000. Finally, Frank Rimerman Advisors LLC boosted its stake in shares of IDEXX Laboratories by 80.6% in the fourth quarter. Frank Rimerman Advisors LLC now owns 995 shares of the company’s stock valued at $673,000 after purchasing an additional 444 shares during the period. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $569.55 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. The business has a 50 day simple moving average of $618.12 and a 200-day simple moving average of $659.08. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $769.98. The stock has a market capitalization of $45.24 billion, a PE ratio of 43.58, a price-to-earnings-growth ratio of 3.46 and a beta of 1.72.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, February 2nd. The company reported $3.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.93 by $0.15. The company had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. IDEXX Laboratories’s revenue was up 14.3% compared to the same quarter last year. During the same period in the previous year, the company posted $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Wall Street Zen cut shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Weiss Ratings downgraded shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. Barclays reduced their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Piper Sandler decreased their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a report on Monday, February 9th. Finally, UBS Group lowered their target price on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a research note on Tuesday, February 3rd. Seven research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $772.22.

Insider Buying and Selling

In other news, Director Sophie V. Vandebroek sold 1,464 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total value of $920,299.68. Following the completion of the sale, the director directly owned 648 shares of the company’s stock, valued at $407,345.76. This trade represents a 69.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Nimrata Hunt sold 1,758 shares of the company’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total value of $1,115,574.06. Following the transaction, the executive vice president directly owned 18,141 shares in the company, valued at $11,511,734.37. This represents a 8.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 45,957 shares of company stock worth $29,862,109 in the last three months. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.